MAIA Biotechnology Showcases Promising THIO-101 Trial Data

An announcement from MAIA Biotechnology, Inc. ( (MAIA) ) is now available.

MAIA Biotechnology, Inc. presented a poster at the 2025 ASCO Annual Meeting, showcasing efficacy data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO in combination with cemiplimab for advanced non-small cell lung cancer patients who have not responded to standard treatments. The poster, which will be available on the company’s website, highlights the potential impact on the company’s operations and its positioning within the oncology sector.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative oncology treatments. The company is primarily engaged in advancing therapies for cancer patients, particularly those with unmet medical needs.

Average Trading Volume: 200,242

Technical Sentiment Signal: Sell

Current Market Cap: $54.25M

See more insights into MAIA stock on TipRanks’ Stock Analysis page.